Kymera Therapeutics KYMR Stock
Kymera Therapeutics Price Chart
Kymera Therapeutics KYMR Financial and Trading Overview
| Kymera Therapeutics stock price | 23.69 USD |
| Previous Close | 25.8 USD |
| Open | 25.58 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 1100 |
| Day's Range | 25.58 - 28.43 USD |
| 52 Week Range | 14.48 - 39.85 USD |
| Volume | 728.93K USD |
| Avg. Volume | 508.95K USD |
| Market Cap | 1.53B USD |
| Beta (5Y Monthly) | 1.723356 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.98 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.94 USD |
KYMR Valuation Measures
| Enterprise Value | 1.09B USD |
| Trailing P/E | N/A |
| Forward P/E | -8.566564 |
| PEG Ratio (5 yr expected) | -5.05 |
| Price/Sales (ttm) | 32.791233 |
| Price/Book (mrq) | 3.2834935 |
| Enterprise Value/Revenue | 23.294 |
| Enterprise Value/EBITDA | -6.483 |
Trading Information
Kymera Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.723356 |
| 52-Week Change | 75.45% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 39.85 USD |
| 52 Week Low | 14.48 USD |
| 50-Day Moving Average | 29.64 USD |
| 200-Day Moving Average | 29.06 USD |
KYMR Share Statistics
| Avg. Volume (3 month) | 508.95K USD |
| Avg. Daily Volume (10-Days) | 838.75K USD |
| Shares Outstanding | 55.31M |
| Float | 36.73M |
| Short Ratio | 17.87 |
| % Held by Insiders | 7.13% |
| % Held by Institutions | 105.45% |
| Shares Short | 9.24M |
| Short % of Float | 18.95% |
| Short % of Shares Outstanding | 16.71% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -363.50% |
| Gross Margin | -265.39% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -18.018% |
| Return on Equity (ttm) | -35.71% |
Income Statement
| Revenue (ttm) | 46.67M USD |
| Revenue Per Share (ttm) | 0.84 USD |
| Quarterly Revenue Growth (yoy) | -1.60% |
| Gross Profit (ttm) | -117422000 USD |
| EBITDA | -167680000 USD |
| Net Income Avi to Common (ttm) | -159052000 USD |
| Diluted EPS (ttm) | -2.83 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 396.88M USD |
| Total Cash Per Share (mrq) | 7.24 USD |
| Total Debt (mrq) | 68.76M USD |
| Total Debt/Equity (mrq) | 14.88 USD |
| Current Ratio (mrq) | 6.645 |
| Book Value Per Share (mrq) | 8.427 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -156758000 USD |
| Levered Free Cash Flow (ttm) | -103181376 USD |
Profile of Kymera Therapeutics
| Country | United States |
| State | MA |
| City | Watertown |
| Address | 200 Arsenal Yards Boulevard |
| ZIP | 02472 |
| Phone | 857 285 5300 |
| Website | https://www.kymeratx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 174 |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Q&A For Kymera Therapeutics Stock
What is a current KYMR stock price?
Kymera Therapeutics KYMR stock price today per share is 23.69 USD.
How to purchase Kymera Therapeutics stock?
You can buy KYMR shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kymera Therapeutics?
The stock symbol or ticker of Kymera Therapeutics is KYMR.
Which industry does the Kymera Therapeutics company belong to?
The Kymera Therapeutics industry is Biotechnology.
How many shares does Kymera Therapeutics have in circulation?
The max supply of Kymera Therapeutics shares is 64.94M.
What is Kymera Therapeutics Price to Earnings Ratio (PE Ratio)?
Kymera Therapeutics PE Ratio is now.
What was Kymera Therapeutics earnings per share over the trailing 12 months (TTM)?
Kymera Therapeutics EPS is -2.98 USD over the trailing 12 months.
Which sector does the Kymera Therapeutics company belong to?
The Kymera Therapeutics sector is Healthcare.
Kymera Therapeutics KYMR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
| NASDAQ Global Market Composite NQGM | 1737.75 USD — |
-6
|
— — | 1724.84 USD — | 1770.8 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2030.58 USD — |
-6.66
|
— — | 2030.36 USD — | 2092.28 USD — | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2654.77 USD — |
-6.16
|
— — | 2649.3 USD — | 2734.22 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4130.78 USD — |
-1.87
|
— — | 4123.5 USD — | 4185.42 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
- {{ link.label }} {{link}}